UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2024

Commission File Number: **001-42128**

Telix Pharmaceuticals Limited

(Translation of registrant's name into English)

55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On December 30, 2024, Telix Pharmaceuticals Limited filed with the Australian Securities Exchange (i) an announcement captioned "Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging," a copy of which is attached to this Form 6-K as Exhibit 99.1, and (ii) an announcement captioned "Managing Director and Group CEO Remuneration Update," a copy of which is attached to this Form 6-K as Exhibit 99.2.

99.1	Press release dated December 30, 2024
99.2	ASX announcement dated December 30, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Telix Pharmaceuticals Limited

Date: December 30, 2024

By: /s/ Genevieve Ryan

Name: Genevieve Ryan
Title: Company Secretary

Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 30 December 2024. Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®[1], ^{89}Zr- girentuximab) kidney cancer imaging[2].

TLX250-CDx is an investigational PET[3] drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix's successful urology imaging franchise.

The FDA is expected to advise the PDUFA[4] goal date following the 60-day administrative review of the application.

Kevin Richardson, Chief Executive Officer, Precision Medicine at Telix, stated, "We are pleased to be progressing the BLA for TLX250-CDx, which has been granted Breakthrough designation, and may therefore be eligible for priority review. Telix continues to target a full U.S. commercial launch in 2025 addressing a major unmet medical need for patients with suspected ccRCC."

About TLX250-CDx

TLX250-CDx (Zircaix®[1]) is an investigational PET agent that is under development for the diagnosis and characterisation of ccRCC. Telix's pivotal Phase III ZIRCON trial (ClinicalTrials.gov ID: NCT03849118) evaluating TLX250-CDx in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive-predictive value for ccRCC across three independent radiology readers[5]. Telix believes this demonstrated the ability of TLX250-CDx to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterising ccRCC. Confidence intervals exceeded expectations amongst all three readers, showing evidence of high accuracy and consistency of interpretation.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

[1] Brand name subject to final regulatory approval.
[2] Telix ASX disclosure 31 July 2024. The FDA requested additional data demonstrating adequate sterility assurance during dispensing of TLX250-CDx in the radiopharmacy production environment.
[3] Positron emission tomography.
[4] Prescription Drug User Fee Act.

Telix's lead imaging product, gallium-68 (^{68}Ga) gozetotide injection (also known as ^{68}Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[6], by the Australian Therapeutic Goods Administration (TGA) [7], and by Health Canada[8]. No other Telix product has received a marketing authorisation in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

[5] Shuch et al. *Lancet Oncol.* 2024. Telix ASX disclosures 7 November 2022.
[6] Telix ASX disclosure 20 December 2021.
[7] Telix ASX disclosure 2 November 2021.
[8] Telix ASX disclosure 14 October 2022.

Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX ANNOUNCEMENT

Managing Director and Group CEO Remuneration Update

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 30 December 2024. Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today advises that following its annual review of Board and executive remuneration, the Company's Board of Directors has approved an increase to the total remuneration package of the Managing Director and Group Chief Executive Officer (MD & CEO), Dr Christian Behrenbruch, effective 1 January 2025.

The increase was awarded to reflect the achievement of key business inflection points, an expanded scope in responsibilities reflecting Telix's growth and trajectory, and to achieve remuneration for the MD & CEO that is more closely aligned to the market median of the competitive global talent market.

In accordance with ASX Listing Rule 3.16.4 the material changes to Dr Behrenbruch's employment agreement are set out in Schedule 1.

Further details will be provided in the 2024 Remuneration report (within the 2024 Annual Report) as well as in the 2025 Annual General Meeting Notice of Meeting.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Schedule 1

The material changes to the employment agreement between Dr Behrenbruch and the Company, effective 1 January 2025, are as follows:

Total Base Pay	AU$799,092.
Total Fixed Remuneration (TFR)	AU$892,985. TFR represents Base Pay plus statutory superannuation contributions paid in equal monthly cash instalments over the year, and packaged benefits. Australian Executive Key Management Personnel (KMP) can choose to cap their superannuation at the statutory superannuation maximum and receive the additional 11.5% (for 1 January to 30 June 2025) and 12 % (for 1 July to 31 December 2025) over the maximum as base salary.
Short Term Variable Reward (STVR)	AU$879,001 (target and maximum). At the end of Telix's financial year (31 December), the Board determines STVR payable to the MD & CEO based on a maximum opportunity of 110% of Base Pay, linked to corporate objectives. The maximum STVR the MD & CEO may achieve is 100% of target (there is no over-earn potential). From 1 January 2025, 50% of the STVR outcome will be granted as Deferred Share Rights restricted for 12 months to approximately February 2027, with the remaining 50% of the STVR outcome paid in cash in February 2026. All information regarding the Deferred Share Rights and 2024 outcomes will be detailed in the 2024 Remuneration report. Any Deferred Share Rights proposed to be granted to the MD & CEO will be subject to shareholder approval and will be included as a shareholder resolution at the Company's Annual General Meeting held in 2026 as required.
Long Term Variable Reward (LTVR)	AU$1,198,638 (at target), with a maximum 150% available at stretch. LTVR is granted using Performance Share Appreciation Rights (PSARs) and is subject to the achievement of 3-year performance and vesting conditions. Details regarding the 2025 PSARs will be provided in the 2024 Remuneration report, as part of the 2024 Annual Report. 2025 PSARs proposed to be granted to the MD & CEO will be subject to shareholder approval and will be included as a shareholder resolution at the Company's Annual General Meeting held in 2025 as required.
Notice Period	6 months (effective 31 December 2024).